However, the lack of an additional second molecular mechanism driven by JAK2 exon 16 mutations, unlike JAK2 p. V617F, may explain why ALL-associated JAK2 mutations require CRLF2 overexpression to cooperatively drive malignant transformation and subsequent leukemogenesis. Here, CRLF2 is linked to acute lymphoblastic leukemia.